<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N570965c125ef4d65a95fde109818d547 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N570965c125ef4d65a95fde109818d547 <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N570965c125ef4d65a95fde109818d547 <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N570965c125ef4d65a95fde109818d547.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesIdentification/InternationalSecuritiesIdentificationNumber> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesIdentification/TickerSymbol> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q8148> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q8148> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N61a0baf9863e4f3d8c04a4a90f6556f8 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N61a0baf9863e4f3d8c04a4a90f6556f8 <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N61a0baf9863e4f3d8c04a4a90f6556f8 <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N61a0baf9863e4f3d8c04a4a90f6556f8.
_:N7572de928e5c4addbca355d5294827cb <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7572de928e5c4addbca355d5294827cb <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N7572de928e5c4addbca355d5294827cb <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N7572de928e5c4addbca355d5294827cb.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N1b1f3aac97104454b29d73801571b796 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N1b1f3aac97104454b29d73801571b796 <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N1b1f3aac97104454b29d73801571b796 <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N1b1f3aac97104454b29d73801571b796.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/OwnershipAndControl/Executives/Auditor> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb92d4043d0da4afe84f6301bbcddf9af <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb92d4043d0da4afe84f6301bbcddf9af <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:Nb92d4043d0da4afe84f6301bbcddf9af <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Nb92d4043d0da4afe84f6301bbcddf9af.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesIdentification/InternationalSecuritiesIdentificationNumber> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/Exchange> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesIdentification/TickerSymbol> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q8148> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q8148> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N69c7d511ab0d4cb89dedfd857c006aab <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N69c7d511ab0d4cb89dedfd857c006aab <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N69c7d511ab0d4cb89dedfd857c006aab <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N69c7d511ab0d4cb89dedfd857c006aab.
_:Nc8128212ec484158b0802f1a54843ded <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc8128212ec484158b0802f1a54843ded <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:Nc8128212ec484158b0802f1a54843ded <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nc8128212ec484158b0802f1a54843ded.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0af310e5298b4795874d189a0b057a5f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0af310e5298b4795874d189a0b057a5f <https://spec.edmcouncil.org/fibo/ontology/FND/Accounting/CurrencyAmount/hasCurrency> <https://www.wikidata.org/entity/Q4916>.
_:N0af310e5298b4795874d189a0b057a5f <http://www.w3.org/1999/02/22-rdf-syntax-ns#label> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N0af310e5298b4795874d189a0b057a5f.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/OwnershipAndControl/Executives/Auditor> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0d391c0702cf4c95af8edcd03668f0be <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0d391c0702cf4c95af8edcd03668f0be <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0d391c0702cf4c95af8edcd03668f0be <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N0d391c0702cf4c95af8edcd03668f0be.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc62537ed4cb14d4da0b95562377146a1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc62537ed4cb14d4da0b95562377146a1 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc62537ed4cb14d4da0b95562377146a1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nc62537ed4cb14d4da0b95562377146a1.
_:N8245c9876f9e45e8a0795350a5290e67 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N8245c9876f9e45e8a0795350a5290e67 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N8245c9876f9e45e8a0795350a5290e67 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N8245c9876f9e45e8a0795350a5290e67.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ned1c0d42c1584365bf2624ab52f28553 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ned1c0d42c1584365bf2624ab52f28553 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ned1c0d42c1584365bf2624ab52f28553 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ned1c0d42c1584365bf2624ab52f28553.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4b57540f0bd34321a8e119006b6f5322 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4b57540f0bd34321a8e119006b6f5322 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4b57540f0bd34321a8e119006b6f5322 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N4b57540f0bd34321a8e119006b6f5322.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/AccountingFramework> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nfcd26b8621f142f4a2323706e8ec5970 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nfcd26b8621f142f4a2323706e8ec5970 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nfcd26b8621f142f4a2323706e8ec5970 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nfcd26b8621f142f4a2323706e8ec5970.
_:N70bc96075c7349f4a867722e465ab569 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N70bc96075c7349f4a867722e465ab569 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N70bc96075c7349f4a867722e465ab569 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N70bc96075c7349f4a867722e465ab569.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb3e1cfb81d0241d7922fe691677d3214 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb3e1cfb81d0241d7922fe691677d3214 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nb3e1cfb81d0241d7922fe691677d3214 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nb3e1cfb81d0241d7922fe691677d3214.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ncc2f5ec5d6d949aab59028e76f951c66 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ncc2f5ec5d6d949aab59028e76f951c66 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ncc2f5ec5d6d949aab59028e76f951c66 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Ncc2f5ec5d6d949aab59028e76f951c66.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N04ae08d4df2648cb91913477aa177690 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N04ae08d4df2648cb91913477aa177690 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N04ae08d4df2648cb91913477aa177690 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N04ae08d4df2648cb91913477aa177690.
_:Nf578bf2453eb439791506ef27258246e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nf578bf2453eb439791506ef27258246e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nf578bf2453eb439791506ef27258246e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nf578bf2453eb439791506ef27258246e.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N9dd4745a44ff43acbd0130c48522c50a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9dd4745a44ff43acbd0130c48522c50a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9dd4745a44ff43acbd0130c48522c50a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N9dd4745a44ff43acbd0130c48522c50a.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N13ddb647cc954f4bba0948fbd0c26c9a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N13ddb647cc954f4bba0948fbd0c26c9a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N13ddb647cc954f4bba0948fbd0c26c9a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N13ddb647cc954f4bba0948fbd0c26c9a.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc7ab055c61234344bfdfb401757d088e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc7ab055c61234344bfdfb401757d088e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc7ab055c61234344bfdfb401757d088e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nc7ab055c61234344bfdfb401757d088e.
_:Nc107a486d59b4e63aeac99dd7128a479 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc107a486d59b4e63aeac99dd7128a479 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc107a486d59b4e63aeac99dd7128a479 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nc107a486d59b4e63aeac99dd7128a479.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N95caae5ef878405cb5857590521f0a91 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N95caae5ef878405cb5857590521f0a91 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N95caae5ef878405cb5857590521f0a91 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N95caae5ef878405cb5857590521f0a91.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N9634dcef184346b9945ee3dae74b627a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9634dcef184346b9945ee3dae74b627a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9634dcef184346b9945ee3dae74b627a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N9634dcef184346b9945ee3dae74b627a.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd71d8c75593d434998e3c59178ce128c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd71d8c75593d434998e3c59178ce128c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd71d8c75593d434998e3c59178ce128c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nd71d8c75593d434998e3c59178ce128c.
_:Na6cc4126a31e4c66801d7b4ff014e563 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na6cc4126a31e4c66801d7b4ff014e563 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na6cc4126a31e4c66801d7b4ff014e563 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Na6cc4126a31e4c66801d7b4ff014e563.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N7813469c45de4886bd74ac93ba7cbec5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7813469c45de4886bd74ac93ba7cbec5 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N7813469c45de4886bd74ac93ba7cbec5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N7813469c45de4886bd74ac93ba7cbec5.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N1a887d13e4b04a4faf117274538a06ef <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N1a887d13e4b04a4faf117274538a06ef <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N1a887d13e4b04a4faf117274538a06ef <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N1a887d13e4b04a4faf117274538a06ef.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc73353dbed9f4bffa201db54fa7f7c81 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc73353dbed9f4bffa201db54fa7f7c81 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc73353dbed9f4bffa201db54fa7f7c81 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nc73353dbed9f4bffa201db54fa7f7c81.
_:N2e470bd31ccb483aa96896a4f11a63e4 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N2e470bd31ccb483aa96896a4f11a63e4 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N2e470bd31ccb483aa96896a4f11a63e4 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N2e470bd31ccb483aa96896a4f11a63e4.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N40a82664f7bd4bc494ed3e7aac4903fd <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N40a82664f7bd4bc494ed3e7aac4903fd <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N40a82664f7bd4bc494ed3e7aac4903fd <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N40a82664f7bd4bc494ed3e7aac4903fd.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nae6daeaef641458e81409106328b725a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nae6daeaef641458e81409106328b725a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nae6daeaef641458e81409106328b725a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Nae6daeaef641458e81409106328b725a.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N041438b51d3c43f2829a4254254c29f7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N041438b51d3c43f2829a4254254c29f7 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N041438b51d3c43f2829a4254254c29f7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N041438b51d3c43f2829a4254254c29f7.
_:N3b32d27d7cf14291847115c22755e1a7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N3b32d27d7cf14291847115c22755e1a7 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N3b32d27d7cf14291847115c22755e1a7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N3b32d27d7cf14291847115c22755e1a7.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N5874d722820f4630b565134ef982962b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N5874d722820f4630b565134ef982962b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N5874d722820f4630b565134ef982962b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N5874d722820f4630b565134ef982962b.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N56b2c1722f704e6db37af1d436313f74 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N56b2c1722f704e6db37af1d436313f74 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N56b2c1722f704e6db37af1d436313f74 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N56b2c1722f704e6db37af1d436313f74.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N1249744e86d04974a0724e990ddb7252 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N1249744e86d04974a0724e990ddb7252 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N1249744e86d04974a0724e990ddb7252 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N1249744e86d04974a0724e990ddb7252.
_:N795c1bbcd45d445a87aef6eda85dcb75 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N795c1bbcd45d445a87aef6eda85dcb75 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N795c1bbcd45d445a87aef6eda85dcb75 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N795c1bbcd45d445a87aef6eda85dcb75.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N97c37628ee7b4130b3075e33afd1f989 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N97c37628ee7b4130b3075e33afd1f989 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N97c37628ee7b4130b3075e33afd1f989 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N97c37628ee7b4130b3075e33afd1f989.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc17c4ff3a1d741d1949f9781be6475ea <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc17c4ff3a1d741d1949f9781be6475ea <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc17c4ff3a1d741d1949f9781be6475ea <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Nc17c4ff3a1d741d1949f9781be6475ea.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/Dividend> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N293fafc59dbd464197a32d059059c661 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N293fafc59dbd464197a32d059059c661 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N293fafc59dbd464197a32d059059c661 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N293fafc59dbd464197a32d059059c661.
_:N5535cb883ef6479c8f4a0caf153fe74c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N5535cb883ef6479c8f4a0caf153fe74c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N5535cb883ef6479c8f4a0caf153fe74c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N5535cb883ef6479c8f4a0caf153fe74c.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N86a5953584c747118cbed6e042f8a63f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N86a5953584c747118cbed6e042f8a63f <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N86a5953584c747118cbed6e042f8a63f <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N86a5953584c747118cbed6e042f8a63f.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N9911ae26ecd34750a1d8aac300c21054 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9911ae26ecd34750a1d8aac300c21054 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9911ae26ecd34750a1d8aac300c21054 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N9911ae26ecd34750a1d8aac300c21054.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4c8eacf36b104c38adec988bd7de3fb9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4c8eacf36b104c38adec988bd7de3fb9 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4c8eacf36b104c38adec988bd7de3fb9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N4c8eacf36b104c38adec988bd7de3fb9.
_:Ncec39ed27aa341fe940283ba7fa6f71b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ncec39ed27aa341fe940283ba7fa6f71b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ncec39ed27aa341fe940283ba7fa6f71b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Ncec39ed27aa341fe940283ba7fa6f71b.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N370ea73e8cec4694b5317b24d89c22c7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N370ea73e8cec4694b5317b24d89c22c7 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N370ea73e8cec4694b5317b24d89c22c7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N370ea73e8cec4694b5317b24d89c22c7.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na0aec3afa7c2444b856c894f20e85c13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na0aec3afa7c2444b856c894f20e85c13 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na0aec3afa7c2444b856c894f20e85c13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:Na0aec3afa7c2444b856c894f20e85c13.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N04a2bc5f44744c568f0a8c5f2927232a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N04a2bc5f44744c568f0a8c5f2927232a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N04a2bc5f44744c568f0a8c5f2927232a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N04a2bc5f44744c568f0a8c5f2927232a.
_:N11a6c232d610456298f81373d1a75a46 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N11a6c232d610456298f81373d1a75a46 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N11a6c232d610456298f81373d1a75a46 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N11a6c232d610456298f81373d1a75a46.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N05537aa4296b414cb84ee451eb1adf13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N05537aa4296b414cb84ee451eb1adf13 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N05537aa4296b414cb84ee451eb1adf13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N05537aa4296b414cb84ee451eb1adf13.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N3c950eb49bad4aba9c9e165911af3b6f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N3c950eb49bad4aba9c9e165911af3b6f <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N3c950eb49bad4aba9c9e165911af3b6f <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N3c950eb49bad4aba9c9e165911af3b6f.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ncc2c9241775b4fde8c79c7ca85158afc <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ncc2c9241775b4fde8c79c7ca85158afc <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ncc2c9241775b4fde8c79c7ca85158afc <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ncc2c9241775b4fde8c79c7ca85158afc.
_:N96c324faa4334352918b57c7cbeec902 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N96c324faa4334352918b57c7cbeec902 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N96c324faa4334352918b57c7cbeec902 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N96c324faa4334352918b57c7cbeec902.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nae64c1a28c3e4ae6aca0e8df5a0d21fa <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nae64c1a28c3e4ae6aca0e8df5a0d21fa <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nae64c1a28c3e4ae6aca0e8df5a0d21fa <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nae64c1a28c3e4ae6aca0e8df5a0d21fa.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N6bf8efdc545643ec8e3847b296ed6db5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N6bf8efdc545643ec8e3847b296ed6db5 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N6bf8efdc545643ec8e3847b296ed6db5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/hasOfferingPrice> _:N6bf8efdc545643ec8e3847b296ed6db5.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/InvestmentObjectiveBusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ne58440124169440ea7fdaa0602bfd7f1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ne58440124169440ea7fdaa0602bfd7f1 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ne58440124169440ea7fdaa0602bfd7f1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ne58440124169440ea7fdaa0602bfd7f1.
_:Na34eb10732e347a8be54221ba07bdead <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na34eb10732e347a8be54221ba07bdead <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na34eb10732e347a8be54221ba07bdead <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Na34eb10732e347a8be54221ba07bdead.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0150c7e3deee4033a5b2533529da8dc0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0150c7e3deee4033a5b2533529da8dc0 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0150c7e3deee4033a5b2533529da8dc0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N0150c7e3deee4033a5b2533529da8dc0.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N829357def49140539f1263d00ccd9763 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N829357def49140539f1263d00ccd9763 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N829357def49140539f1263d00ccd9763 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N829357def49140539f1263d00ccd9763.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb4eb0a6b6fdb489c8639a01b73d50b5a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb4eb0a6b6fdb489c8639a01b73d50b5a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nb4eb0a6b6fdb489c8639a01b73d50b5a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nb4eb0a6b6fdb489c8639a01b73d50b5a.
_:N6f0d0b05098d4a638483ff6915c7f4a0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N6f0d0b05098d4a638483ff6915c7f4a0 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N6f0d0b05098d4a638483ff6915c7f4a0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N6f0d0b05098d4a638483ff6915c7f4a0.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N41dc0165044a42f889978369dda2c221 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N41dc0165044a42f889978369dda2c221 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N41dc0165044a42f889978369dda2c221 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N41dc0165044a42f889978369dda2c221.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N096253ce3b7a4b9297ec8fc097433b6b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N096253ce3b7a4b9297ec8fc097433b6b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N096253ce3b7a4b9297ec8fc097433b6b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N096253ce3b7a4b9297ec8fc097433b6b.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N1dba4fcc00c2428b9de0a49899331f65 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N1dba4fcc00c2428b9de0a49899331f65 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N1dba4fcc00c2428b9de0a49899331f65 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N1dba4fcc00c2428b9de0a49899331f65.
_:Ndd36cdf0eae2410db63080ea76324eb3 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ndd36cdf0eae2410db63080ea76324eb3 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ndd36cdf0eae2410db63080ea76324eb3 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Ndd36cdf0eae2410db63080ea76324eb3.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N2a88374a2cb04d6f84388f4e5978d27a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N2a88374a2cb04d6f84388f4e5978d27a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N2a88374a2cb04d6f84388f4e5978d27a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N2a88374a2cb04d6f84388f4e5978d27a.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N62d7e1a604af424a809b472c4fffb88d <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N62d7e1a604af424a809b472c4fffb88d <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N62d7e1a604af424a809b472c4fffb88d <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N62d7e1a604af424a809b472c4fffb88d.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na63941f95cba4e1b9547510a8b160d3c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na63941f95cba4e1b9547510a8b160d3c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na63941f95cba4e1b9547510a8b160d3c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Na63941f95cba4e1b9547510a8b160d3c.
_:Ne53862c576174793a4cef40ce5e826ea <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ne53862c576174793a4cef40ce5e826ea <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ne53862c576174793a4cef40ce5e826ea <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Ne53862c576174793a4cef40ce5e826ea.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd8f684b28bbb40cabb418373ed5adce1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd8f684b28bbb40cabb418373ed5adce1 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd8f684b28bbb40cabb418373ed5adce1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nd8f684b28bbb40cabb418373ed5adce1.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nea942a3e13c942d19cad101e4dc88cde <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nea942a3e13c942d19cad101e4dc88cde <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nea942a3e13c942d19cad101e4dc88cde <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nea942a3e13c942d19cad101e4dc88cde.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ne0e433deb1304d3faa11d5e2812a1d23 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ne0e433deb1304d3faa11d5e2812a1d23 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ne0e433deb1304d3faa11d5e2812a1d23 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ne0e433deb1304d3faa11d5e2812a1d23.
_:N9043b9bbff9d4e5a8a3cd2862438d905 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9043b9bbff9d4e5a8a3cd2862438d905 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9043b9bbff9d4e5a8a3cd2862438d905 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N9043b9bbff9d4e5a8a3cd2862438d905.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nf7edc1f5df6e4431ae62415a6afee1b5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nf7edc1f5df6e4431ae62415a6afee1b5 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nf7edc1f5df6e4431ae62415a6afee1b5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nf7edc1f5df6e4431ae62415a6afee1b5.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb736ca630dae4cf6acf837fd5fc4c55e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb736ca630dae4cf6acf837fd5fc4c55e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nb736ca630dae4cf6acf837fd5fc4c55e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nb736ca630dae4cf6acf837fd5fc4c55e.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4b4bb7b630a2417c83009a6da5dcde46 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4b4bb7b630a2417c83009a6da5dcde46 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4b4bb7b630a2417c83009a6da5dcde46 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N4b4bb7b630a2417c83009a6da5dcde46.
_:Nae6c3a30fb7e4d38b982c414011998f5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nae6c3a30fb7e4d38b982c414011998f5 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nae6c3a30fb7e4d38b982c414011998f5 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nae6c3a30fb7e4d38b982c414011998f5.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N72b8e53ae2dd461ab45a7f0e0aa50330 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N72b8e53ae2dd461ab45a7f0e0aa50330 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N72b8e53ae2dd461ab45a7f0e0aa50330 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N72b8e53ae2dd461ab45a7f0e0aa50330.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N9f244c2676e748498ba8b019ec34ccbc <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9f244c2676e748498ba8b019ec34ccbc <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9f244c2676e748498ba8b019ec34ccbc <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N9f244c2676e748498ba8b019ec34ccbc.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N25c3831f25f14ebf8cf440976f5eb9af <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N25c3831f25f14ebf8cf440976f5eb9af <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N25c3831f25f14ebf8cf440976f5eb9af <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N25c3831f25f14ebf8cf440976f5eb9af.
_:Nfadd89ab450a483abd70b1bb261cf5ff <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nfadd89ab450a483abd70b1bb261cf5ff <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nfadd89ab450a483abd70b1bb261cf5ff <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nfadd89ab450a483abd70b1bb261cf5ff.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N946d173842dd44b3911c47eba4c0bc05 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N946d173842dd44b3911c47eba4c0bc05 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N946d173842dd44b3911c47eba4c0bc05 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N946d173842dd44b3911c47eba4c0bc05.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N1d2080cbd93d49db850677ec56174267 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N1d2080cbd93d49db850677ec56174267 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N1d2080cbd93d49db850677ec56174267 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N1d2080cbd93d49db850677ec56174267.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ncac5f26851314b3583941db8a48353cd <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ncac5f26851314b3583941db8a48353cd <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ncac5f26851314b3583941db8a48353cd <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ncac5f26851314b3583941db8a48353cd.
_:N4ebca29d7a5e4ac8b0a953ffb0a8c44b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4ebca29d7a5e4ac8b0a953ffb0a8c44b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4ebca29d7a5e4ac8b0a953ffb0a8c44b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N4ebca29d7a5e4ac8b0a953ffb0a8c44b.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb87e6e5e052943fd8aba187bad2bc215 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb87e6e5e052943fd8aba187bad2bc215 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nb87e6e5e052943fd8aba187bad2bc215 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nb87e6e5e052943fd8aba187bad2bc215.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N8918a95bd84b4033a06f6cf26b0678b7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N8918a95bd84b4033a06f6cf26b0678b7 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N8918a95bd84b4033a06f6cf26b0678b7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N8918a95bd84b4033a06f6cf26b0678b7.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N8e6171c2c55f4c95876d78e39e884a88 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N8e6171c2c55f4c95876d78e39e884a88 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N8e6171c2c55f4c95876d78e39e884a88 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N8e6171c2c55f4c95876d78e39e884a88.
_:Nf0bcad5befb342e087a1c9fad65c6a45 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nf0bcad5befb342e087a1c9fad65c6a45 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nf0bcad5befb342e087a1c9fad65c6a45 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nf0bcad5befb342e087a1c9fad65c6a45.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nf9a1452c57c44d31a0cbbd850c86b265 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nf9a1452c57c44d31a0cbbd850c86b265 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nf9a1452c57c44d31a0cbbd850c86b265 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nf9a1452c57c44d31a0cbbd850c86b265.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nfd944f0ba6414b289bbe8ecfaf4275c6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nfd944f0ba6414b289bbe8ecfaf4275c6 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nfd944f0ba6414b289bbe8ecfaf4275c6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nfd944f0ba6414b289bbe8ecfaf4275c6.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N8bb0ef537a534bbc8089afc137f71801 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N8bb0ef537a534bbc8089afc137f71801 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N8bb0ef537a534bbc8089afc137f71801 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N8bb0ef537a534bbc8089afc137f71801.
_:N53b1a8108ce74af28d4ba7c77e2960ef <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N53b1a8108ce74af28d4ba7c77e2960ef <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N53b1a8108ce74af28d4ba7c77e2960ef <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N53b1a8108ce74af28d4ba7c77e2960ef.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd02f9e8010474ff081992ccdc1982545 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd02f9e8010474ff081992ccdc1982545 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd02f9e8010474ff081992ccdc1982545 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nd02f9e8010474ff081992ccdc1982545.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0dc7c730c3674a3892d41b1572aecac0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0dc7c730c3674a3892d41b1572aecac0 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0dc7c730c3674a3892d41b1572aecac0 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N0dc7c730c3674a3892d41b1572aecac0.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na1efbaa0e9394a05835bcff904d32b2a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na1efbaa0e9394a05835bcff904d32b2a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na1efbaa0e9394a05835bcff904d32b2a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Na1efbaa0e9394a05835bcff904d32b2a.
_:N6077ad1d3c754f488c9460d027605664 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N6077ad1d3c754f488c9460d027605664 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N6077ad1d3c754f488c9460d027605664 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N6077ad1d3c754f488c9460d027605664.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na6474b5428964447b991c2a2af90d680 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na6474b5428964447b991c2a2af90d680 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na6474b5428964447b991c2a2af90d680 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Na6474b5428964447b991c2a2af90d680.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N24cb72b6924c42e2b96443075e9cee8f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N24cb72b6924c42e2b96443075e9cee8f <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N24cb72b6924c42e2b96443075e9cee8f <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N24cb72b6924c42e2b96443075e9cee8f.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N74e04188480d4f51b1be2f53efee5621 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N74e04188480d4f51b1be2f53efee5621 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N74e04188480d4f51b1be2f53efee5621 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N74e04188480d4f51b1be2f53efee5621.
_:N5d06dd5f6e454ca888fd160439aa00e1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N5d06dd5f6e454ca888fd160439aa00e1 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N5d06dd5f6e454ca888fd160439aa00e1 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N5d06dd5f6e454ca888fd160439aa00e1.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nb8d8b44611ee4a179b2d1f66dc9e5440 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nb8d8b44611ee4a179b2d1f66dc9e5440 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nb8d8b44611ee4a179b2d1f66dc9e5440 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nb8d8b44611ee4a179b2d1f66dc9e5440.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N7b5f426165854f60a9aa7e0f96762c0d <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7b5f426165854f60a9aa7e0f96762c0d <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N7b5f426165854f60a9aa7e0f96762c0d <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N7b5f426165854f60a9aa7e0f96762c0d.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N911322717b3c4fe799275f129cae9159 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N911322717b3c4fe799275f129cae9159 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N911322717b3c4fe799275f129cae9159 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N911322717b3c4fe799275f129cae9159.
_:N9ded16ebda7c43afbea5214727b8ba1f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9ded16ebda7c43afbea5214727b8ba1f <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9ded16ebda7c43afbea5214727b8ba1f <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N9ded16ebda7c43afbea5214727b8ba1f.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4763e5afd2574f00a8521f13e8f34a17 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4763e5afd2574f00a8521f13e8f34a17 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4763e5afd2574f00a8521f13e8f34a17 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N4763e5afd2574f00a8521f13e8f34a17.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nba8b3cc2a09c4a18a0b30d8d2bb875eb <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nba8b3cc2a09c4a18a0b30d8d2bb875eb <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nba8b3cc2a09c4a18a0b30d8d2bb875eb <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nba8b3cc2a09c4a18a0b30d8d2bb875eb.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nfd4d574054c94c728da764c9e2133414 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nfd4d574054c94c728da764c9e2133414 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nfd4d574054c94c728da764c9e2133414 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nfd4d574054c94c728da764c9e2133414.
_:Nff933f978d1f4cf3a4bbdd4df3194155 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nff933f978d1f4cf3a4bbdd4df3194155 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nff933f978d1f4cf3a4bbdd4df3194155 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nff933f978d1f4cf3a4bbdd4df3194155.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ncb7746ab1af3438ba899b6f97b254d3b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ncb7746ab1af3438ba899b6f97b254d3b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ncb7746ab1af3438ba899b6f97b254d3b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ncb7746ab1af3438ba899b6f97b254d3b.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N7914011763cc47d584b5d6e41df5db5a <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7914011763cc47d584b5d6e41df5db5a <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N7914011763cc47d584b5d6e41df5db5a <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N7914011763cc47d584b5d6e41df5db5a.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N76f7ce8455d54d35bd1c7e01d491fd13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N76f7ce8455d54d35bd1c7e01d491fd13 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N76f7ce8455d54d35bd1c7e01d491fd13 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N76f7ce8455d54d35bd1c7e01d491fd13.
_:N7526c784269c4fd6b9e86255f513d265 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7526c784269c4fd6b9e86255f513d265 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N7526c784269c4fd6b9e86255f513d265 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N7526c784269c4fd6b9e86255f513d265.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ndf10b8d5a2b743928e11c9e9dbe49030 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ndf10b8d5a2b743928e11c9e9dbe49030 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ndf10b8d5a2b743928e11c9e9dbe49030 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ndf10b8d5a2b743928e11c9e9dbe49030.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc9c96bc285d1430aa21cab688990c7ac <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc9c96bc285d1430aa21cab688990c7ac <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc9c96bc285d1430aa21cab688990c7ac <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nc9c96bc285d1430aa21cab688990c7ac.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N04abd75cd4d04e36a05e9a8ec47c4c72 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N04abd75cd4d04e36a05e9a8ec47c4c72 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N04abd75cd4d04e36a05e9a8ec47c4c72 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N04abd75cd4d04e36a05e9a8ec47c4c72.
_:Nbdaba74974304ccf99d0891a28a72907 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nbdaba74974304ccf99d0891a28a72907 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nbdaba74974304ccf99d0891a28a72907 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nbdaba74974304ccf99d0891a28a72907.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N3feddd9aa9594e0db0dcd108bc99eea2 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N3feddd9aa9594e0db0dcd108bc99eea2 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N3feddd9aa9594e0db0dcd108bc99eea2 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N3feddd9aa9594e0db0dcd108bc99eea2.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N8168278830f741c88c2b81d503e8655c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N8168278830f741c88c2b81d503e8655c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N8168278830f741c88c2b81d503e8655c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N8168278830f741c88c2b81d503e8655c.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ne2bce7cec21c4974a3f08f61e870d1be <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ne2bce7cec21c4974a3f08f61e870d1be <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ne2bce7cec21c4974a3f08f61e870d1be <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ne2bce7cec21c4974a3f08f61e870d1be.
_:N0a5036b2da8946d8aa0ac06c869e9d96 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0a5036b2da8946d8aa0ac06c869e9d96 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0a5036b2da8946d8aa0ac06c869e9d96 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N0a5036b2da8946d8aa0ac06c869e9d96.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4fc18a306965411ca73a7b73b0089560 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4fc18a306965411ca73a7b73b0089560 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4fc18a306965411ca73a7b73b0089560 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N4fc18a306965411ca73a7b73b0089560.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd8eaa43371c54307be27db15d1716b99 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd8eaa43371c54307be27db15d1716b99 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd8eaa43371c54307be27db15d1716b99 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nd8eaa43371c54307be27db15d1716b99.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc71d616bec954593a6378c2fd7156882 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc71d616bec954593a6378c2fd7156882 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc71d616bec954593a6378c2fd7156882 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nc71d616bec954593a6378c2fd7156882.
_:N0d6a3cec26524ce49da858f12f552f16 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0d6a3cec26524ce49da858f12f552f16 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0d6a3cec26524ce49da858f12f552f16 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N0d6a3cec26524ce49da858f12f552f16.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Na9594cdc904b4aa6a671d7b64f2f891e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Na9594cdc904b4aa6a671d7b64f2f891e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Na9594cdc904b4aa6a671d7b64f2f891e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Na9594cdc904b4aa6a671d7b64f2f891e.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N2de5598c21aa42f6a0eafac09b9c12d6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N2de5598c21aa42f6a0eafac09b9c12d6 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N2de5598c21aa42f6a0eafac09b9c12d6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N2de5598c21aa42f6a0eafac09b9c12d6.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Neb6e10d03fee4f1fbbe20ed6c7b1f479 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Neb6e10d03fee4f1fbbe20ed6c7b1f479 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Neb6e10d03fee4f1fbbe20ed6c7b1f479 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Neb6e10d03fee4f1fbbe20ed6c7b1f479.
_:N2ba6fbb3c58c49399e230118a5ae1169 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N2ba6fbb3c58c49399e230118a5ae1169 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N2ba6fbb3c58c49399e230118a5ae1169 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N2ba6fbb3c58c49399e230118a5ae1169.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ne14a7693913c4665a844346036f4e870 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ne14a7693913c4665a844346036f4e870 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ne14a7693913c4665a844346036f4e870 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ne14a7693913c4665a844346036f4e870.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N6ddcec15324749e7b19207c48043c574 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N6ddcec15324749e7b19207c48043c574 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N6ddcec15324749e7b19207c48043c574 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N6ddcec15324749e7b19207c48043c574.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nff0e0ca98b474016bf7748c35144fa7f <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nff0e0ca98b474016bf7748c35144fa7f <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nff0e0ca98b474016bf7748c35144fa7f <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nff0e0ca98b474016bf7748c35144fa7f.
_:N60eba3d247f144d8bc85a0f780ce752b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N60eba3d247f144d8bc85a0f780ce752b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N60eba3d247f144d8bc85a0f780ce752b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N60eba3d247f144d8bc85a0f780ce752b.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N83c0dac36ced4fdfbbdf2f7087c74307 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N83c0dac36ced4fdfbbdf2f7087c74307 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N83c0dac36ced4fdfbbdf2f7087c74307 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N83c0dac36ced4fdfbbdf2f7087c74307.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N9fd43dcfe020467ba58eb57b13c4db97 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N9fd43dcfe020467ba58eb57b13c4db97 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N9fd43dcfe020467ba58eb57b13c4db97 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N9fd43dcfe020467ba58eb57b13c4db97.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4a8b857e51ce49189dce27860bd8ae6b <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4a8b857e51ce49189dce27860bd8ae6b <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4a8b857e51ce49189dce27860bd8ae6b <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N4a8b857e51ce49189dce27860bd8ae6b.
_:N7c9a12cc1e8a436c813adc22ee58b415 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N7c9a12cc1e8a436c813adc22ee58b415 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N7c9a12cc1e8a436c813adc22ee58b415 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N7c9a12cc1e8a436c813adc22ee58b415.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N0da005f60ee148a896fc842e0f8d2dc6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N0da005f60ee148a896fc842e0f8d2dc6 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N0da005f60ee148a896fc842e0f8d2dc6 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N0da005f60ee148a896fc842e0f8d2dc6.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ned6dd13fc5254d39ab61c9148eea63dd <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ned6dd13fc5254d39ab61c9148eea63dd <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ned6dd13fc5254d39ab61c9148eea63dd <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Ned6dd13fc5254d39ab61c9148eea63dd.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nf9e1bad7195b4c6dadd999816466553c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nf9e1bad7195b4c6dadd999816466553c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nf9e1bad7195b4c6dadd999816466553c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Nf9e1bad7195b4c6dadd999816466553c.
_:Nda6e67f074dd4a8fb064d0a59bf6db11 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nda6e67f074dd4a8fb064d0a59bf6db11 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nda6e67f074dd4a8fb064d0a59bf6db11 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:Nda6e67f074dd4a8fb064d0a59bf6db11.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N29f4838bf8934cbf9aad950b6f3166b9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N29f4838bf8934cbf9aad950b6f3166b9 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N29f4838bf8934cbf9aad950b6f3166b9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N29f4838bf8934cbf9aad950b6f3166b9.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nc9692b62ebf74e648887e3ba453beec4 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nc9692b62ebf74e648887e3ba453beec4 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nc9692b62ebf74e648887e3ba453beec4 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:Nc9692b62ebf74e648887e3ba453beec4.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Ndefa77973e2e4ad4b72b2d0c426ed140 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Ndefa77973e2e4ad4b72b2d0c426ed140 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Ndefa77973e2e4ad4b72b2d0c426ed140 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:Ndefa77973e2e4ad4b72b2d0c426ed140.
_:N11dcddfe76bf4b3582f8a89ed8f0265c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N11dcddfe76bf4b3582f8a89ed8f0265c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N11dcddfe76bf4b3582f8a89ed8f0265c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N11dcddfe76bf4b3582f8a89ed8f0265c.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N33e7dddef1b34f299637ab9cf4f65918 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N33e7dddef1b34f299637ab9cf4f65918 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N33e7dddef1b34f299637ab9cf4f65918 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q850210> _:N33e7dddef1b34f299637ab9cf4f65918.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N60f608a413b246ec8afdd0a854e6f51c <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N60f608a413b246ec8afdd0a854e6f51c <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N60f608a413b246ec8afdd0a854e6f51c <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N60f608a413b246ec8afdd0a854e6f51c.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd5777792f1b34eb381ef36755be74df9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd5777792f1b34eb381ef36755be74df9 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd5777792f1b34eb381ef36755be74df9 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedGrossProceeds> _:Nd5777792f1b34eb381ef36755be74df9.
_:N846ae1b81d1a43b2ae4e0800f8095e96 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N846ae1b81d1a43b2ae4e0800f8095e96 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N846ae1b81d1a43b2ae4e0800f8095e96 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N846ae1b81d1a43b2ae4e0800f8095e96.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N867db7da73244e20b88fc98e1a90e545 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N867db7da73244e20b88fc98e1a90e545 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N867db7da73244e20b88fc98e1a90e545 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedNetProceeds> _:N867db7da73244e20b88fc98e1a90e545.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>hasAuditedFinancialStatement> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>hasAuditedFinancialStatement> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.w3.org/2000/01/rdf-schema#label> 'OctoPlus N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N4bfe94be5eb64ec9bdee2e520e9df807 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '0.12'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N4bfe94be5eb64ec9bdee2e520e9df807 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N4bfe94be5eb64ec9bdee2e520e9df807 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€0.12 '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/ProductsAndServices/FinancialProductsAndServices/>hasOfferingPrice> _:N4bfe94be5eb64ec9bdee2e520e9df807.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1166072> 'public offering'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P946> 'NL0000345718'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> 'EuronextAmsterdam'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>isTradedOn> <http://www.wikidata.org/entity/Q478720>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q7378915> 'True'^^<https://www.w3.org/2001/XMLSchema#boolean>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/FinancialServicesEntities/>InvestmentBank> 'Kempen & Co N.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Agreements/Contracts/>hasExecutionDate> '2007-11-09'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <http://www.omg.org/techprocess/ab/SpecificationMetadata/hasDescription> 'We are a product-oriented biopharmaceutical company committed to the development of improvedpharmaceutical products based on our proprietary drug delivery technologies that have fewer side effects,increased patient convenience and better efficacy than existing products. We currently have five productcandidates in development, of which two are in Phase II clinical trials. Our lead product candidate, Locteron, isa novel interferon alfa combined with our proprietary PolyActive drug delivery technology for the treatment ofchronic hepatitis C infection. Locteron is designed to require less frequent administration and cause fewer sideeffects than marketed forms of interferon alfa which currently represent the standard of care for this illness. Wehave completed patient treatment in a Phase IIa study of Locteron and intend to commence a Phase IIb clinicaltrial in the middle of 2008. We also intend to commence a separate study in the United States in a difficult-to-treat patient population later this year or in the first quarter of 2008. Our second clinical-stage product candidateis OP-145 CSOM, a novel proprietary peptide therapeutic for the treatment of chronic otitis media, also knownas chronic middle ear infection, that is currently in Phase II clinical trials. In addition, we have three productcandidates in pre-clinical development. OP-286 CR is a controlled-release formulation of a GLP-1 analogue forthe treatment of type II diabetes. We are also developing single shot vaccines based on our proprietaryOctoVAX platform, HBV-OctoVAX for hepatitis B vaccination and JEV-OctoVAX for Japanese encephalitisvaccination.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Advance the development of our lead product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Continue to expand our product candidate portfolio by combining our drug delivery technologies withknown biopharmaceutical drugs or other therapeutics in need of clinical improvement;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Capture value by entering into partnerships with large pharmaceutical or biotechnology companies forour product candidates;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/GoalsAndObjectives/Objectives/>BusinessStrategy> 'Further expand the potential applications of our drug delivery platforms.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> 'Netherlands.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FND/Organizations/FormalOrganizations/>isDomiciledIn> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> 'Netherlands,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/FBC/FunctionalEntities/Markets/>operatesInCountry> <http://www.wikidata.org/entity/Q55>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Debt/Bonds/>hasLockoutPeriod> 'P180D'^^<https://www.w3.org/2001/XMLSchema#duration>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P249> 'OCTO'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'unaudited condensed consolidated interim financial statements as ofand for the six month periods ended 30 June 2006 and 30 June 2007.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> '2006-06-30'^^<https://www.w3.org/2001/XMLSchema#date>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q1337875> 'No minimum amount for the Offer.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> 'healthcare industry'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P452> <http://www.wikidata.org/entity/Q31207>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> 'IFRS'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/BE/LegalEntities/LEIEntities/>hasAccountingStandard> <http://www.wikidata.org/entity/Q176831>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Equities/EquityInstruments/>hasDividendPolicy> 'We currently intend to retain future earnings, if any, to finance the growth and development of our business.As a result, we do not anticipate paying any dividends for the foreseeable future.Our dividend policy will, however, be reviewed from time to time and payment of any future dividends willbe effectively at the discretion of the Executive Board, subject to approval of the Supervisory Board, after takinginto account various factors including our business prospects, cash requirements, financial performance, newproduct development, the payment on our preference shares, to the extent any are issued, in accordance with ourArticles of Association (see “Description of the Share Capital and Corporate Governance – Dividends and OtherDistributions”) and the requirements of Dutch law. Under Dutch law, payment of dividends may be made only ifour shareholders’ equity exceeds the sum of our called up and paid-in share capital plus the reserves required tobe maintained by law and by our Articles of Association.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:N2eb7f5587b5c48938dc284bee941aaa7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '25000000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N2eb7f5587b5c48938dc284bee941aaa7 <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N2eb7f5587b5c48938dc284bee941aaa7 <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€25 million'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedGrossProceeds> _:N2eb7f5587b5c48938dc284bee941aaa7.
_:N085c8af4f6674f76b77f94f80933f12e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '2.1'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:N085c8af4f6674f76b77f94f80933f12e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:N085c8af4f6674f76b77f94f80933f12e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> ' €2.1'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q185142> _:N085c8af4f6674f76b77f94f80933f12e.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'Locteron development activities, including the Phase IIb study, and parallel thereto a study to enabletreatment of difficult-to-treat populations, and subsequent clinical studies and manufacturing andmaterial costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-286 CR development activities, including pre-clinical and clinical development studies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'OP-145 CSOM development activities, including the scheduled Phase III trial and further studies neededto progress OP-145 CSOM to regulatory approval, as well as manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'pre-clinical research and development activities for both OctoVAX product candidates, HBV-OctoVAXand JEV-OctoVAX, as well as subsequent clinical studies and manufacturing and material costs;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'in-licensing or acquiring of additional product candidates or technologies;'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'other general corporate purposes, including expanding our facilities and other capital expenditures, andworking capital; and'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/CIV/Funds/CIV/>InvestmentStrategy> 'acquisitions of complementary businesses if and when they present themselves.'^^<http://www.w3.org/2001/XMLSchema#string>.
_:Nd6c57e415ee34f9885565d974abf039e <http://www.w3.org/1999/02/22-rdf-syntax-ns#value> '22900000'^^<https://www.w3.org/2001/XMLSchema#decimal>.
_:Nd6c57e415ee34f9885565d974abf039e <https://spec.edmcouncil.org/fibo/ontology/FBC/FinancialInstruments/FinancialInstruments/isDenominatedIn> <https://www.wikidata.org/entity/Q4916>.
_:Nd6c57e415ee34f9885565d974abf039e <http://www.w3.org/1999/02/22-rdf-syntax-ns#comment> '€22.9 million '^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://spec.edmcouncil.org/fibo/ontology/placeholder/hasExpectedNetProceeds> _:Nd6c57e415ee34f9885565d974abf039e.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/LOAN/LoanTypes/LoanProducts/>WorkingCapitalPurpose> 'Our current cash resources, together with our existing financing facilities, do not provide us with sufficientworking capital for the next 12 months following the date of this Prospectus. However, we do have sufficientworking capital until into the second quarter of 2008. If the Offer should be withdrawn, we require additionalfunds of approximately €10 million to cover the deficit in our working capital for the next 12 months followingthe date of this Prospectus. In the event we are unable to raise such amount from other sources, we would needto scale back our operations and development programs in order to preserve our cash resources such that wewould have sufficient working capital for the 12 months following the date of this Prospectus. This workingcapital statement covers us and all our current subsidiaries.If the Offer is completed, the expected net proceeds of the Offer together with our current cash resources andour existing financing facilities provide us with sufficient working capital for at least the next 12 monthsfollowing the date of this Prospectus.'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>hasAuditedFinancialStatement> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <<https://spec.edmcouncil.org/fibo/ontology/SEC/Securities/SecuritiesListings/>hasAuditedFinancialStatement> 'audited consolidated financial statements as of and for each of the years in the three-year period ended 31December 2004, 2005 and 2006,'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q740419> '31December 2004, 2005 and 2006'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/Q192907> 'two'^^<http://www.w3.org/2001/XMLSchema#string>.
<http://example.org/entity/#OctoPlusN.V.> <https://wikidata.org/entity/P8571> 'Deloitte Accountants B.V.'^^<http://www.w3.org/2001/XMLSchema#string>.
